



tocol of the National Surgical Adjuvant Breast and Bowel Project (NSABP) (27) at the Jewish General Hospital, Montreal.

A nonequilibrium double-antibody radioimmunoassay, employing recombinant human IGF-I (Amgen, Thousand Oaks, Calif) and an anti-IGF-I antibody provided by the National Institute of Diabetes and Digestive and Kidney Diseases (Bethesda, Md) was used


Table 1. Patient characteristics by treatment group

Characteristic	Treatment group		P
	Tamoxifen	Placebo	
No. of patients	48	21	—
% postmenopausal	75.0	61.9	.27
Mean age (yr)	56.7	52.9	.14
Mean wt (kg)	69.0	64.4	.12
Mean body mass index (kg/m <sup>2</sup> )	26.8	25.6	.42
Mean estrogen receptor levels (fmol/dL)	109.7	122.9	.58
Mean progesterone receptor levels (fmol/dL)	205.7	240.0	.67

Table 2. Mean IGF-I levels by treatment and age group

Age group (yr)	Tamoxifen-treated patients		Placebo-treated patients	
	No. of patients	Mean IGF-I levels (U/mL)	No. of patients	Mean IGF-I levels (U/mL)

response to the drug emphasize tumor-related factors such as selection for estrogen receptor-negative clones during neoplastic progression. The data presented here suggest that host-related factors



human saliva. *J Clin Endocrinol Metab*  
66:1014-1018, 1988

- (32) PHILLIPS LS, UNTERMAN TG: Somatomedin activity in disorders of nutrition and metabolism. *Clin Endocrinol Metab* 13:145-189, 1984
- (33) FRANCHIMONT P, URBAIN-CHOFFRAY D.